Yarrow Bioscience (YARW) Operating Expenses (2016 - 2026)

Yarrow Bioscience (YARW) has reported Operating Expenses for 11 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 57.97% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $24.1 million (down 44.03% YoY), and the FY2025 full-year result was $30.3 million, down 31.31% from the prior year.
• Operating Expenses slipped to $3.2 million in Q2 2026 per YARW's latest filing, from $3.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $13.2 million in Q3 2024 and bottomed at $3.2 million in Q2 2026.
• Historically, Operating Expenses has averaged $8.3 million across 5 years, with a median of $8.2 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses jumped 108.13% in 2024, then tumbled 58.48% in 2026.
• Over 5 years, Operating Expenses stood at $8.0 million in 2022, then fell by 13.54% to $6.9 million in 2023, then jumped by 86.07% to $12.9 million in 2024, then plunged by 40.79% to $7.6 million in 2025, then sank by 57.97% to $3.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $3.2 million, $3.9 million, and $7.6 million for Q2 2026, Q1 2026, and Q2 2025 respectively.